Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Acadia Pharmaceutica (NQ: ACAD)
42.51 USD  -0.73 (-1.69%)
Official Closing Price  /  Updated: 7:36 PM EDT, Oct 22, 2019  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 1,250,500
Open 43.18
Bid (Size) 42.35 (2)
Ask (Size) 42.51 (9)
Prev. Close 43.24
Today's Range 42.27 - 44.10
52wk Range 14.01 - 44.85
Shares Outstanding 124,825,969
Dividend Yield N/A
Performance
YTD
+155.32%
+155.32%
1 Month
+2.16%
+2.16%
3 Month
+91.31%
+91.31%
6 Month
+74.44%
+74.44%
1 Year
+95.36%
+95.36%
Top News
More News
Clinical Trials for Acute Myeloid Leukemia (AML) Drug Therapy Advancing with Encouraging Results
category Featured News
from FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Clinical Trials for Acute Myeloid Leukemia (AML) Drug Therapy Advancing With Encouraging Results
Financialnewsmedia.com News Commentary Read More
from PR Newswire
More News
Read More
ACADIA Pharmaceuticals to Announce Third Quarter 2019 Financial Results on October 30, 2019
from Business Wire News Releases
ACADIA Pharmaceuticals Presents Additional Positive Data from the Phase 2 CLARITY Study with Pimavanserin in Adjunctive Major Depressive Disorder at 2019 Psych Congress
from Business Wire News Releases
ACADIA Pharmaceuticals Announces Late-Breaking Oral Presentation of the Phase 3 HARMONY Study of Pimavanserin in Dementia-Related Psychosis at the Clinical Trials on Alzheimer’s Disease (CTAD) 2019 Me
from Business Wire News Releases
Acadia Pharmaceuticals Moves Up In Market Cap Rank, Passing Leggett & Platt
category Stocks
from Market News Video
ACADIA Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference on October 2, 2019
from Business Wire News Releases
ACADIA Pharmaceuticals Announces that The Journal of Clinical Psychiatry Publishes Positive Phase 2 CLARITY Results for Pimavanserin as Adjunctive Treatment for Patients with Major Depressive Disorder
from Business Wire News Releases
ACADIA Pharmaceuticals Presents New Data on PD Patients Treated with Pimavanserin for Depression at the 2019 International Congress of Parkinson’s Disease and Movement Disorders
from Business Wire News Releases
Add Up The Parts: JKK Could Be Worth $238
category ETFs
from ETF Channel
Stocks Feel Like They Just Want To Explode Higher, And They Just May
category Stocks / Equities , Bonds
from Blogs - TalkMarkets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.